Similarly, a specific class I and II HDAC inhibitor (ITF2357) decreased the proportion of Th17 cells while increasing Tregs in a dose-dependent manner and acetylating Foxp3 in an NZB/W mice model, indicating its potential to relieve systemic lupus erythematosus (SLE) 130. This evidence concerns the gene HDAC9 and systemic lupus erythematosus.